Fig. 2From: Cost-utility analysis of pralatrexate for relapsed or refractory peripheral T-cell lymphoma based on a case-matched historical control study along with single arm clinical trialKaplan-Meier and parametric survival curves of overall survival. (a) corresponds to patients treated with pralatrexate and (b) corresponds to patients treated with conventional chemotherapyBack to article page